Tamoxifen (estrogen antagonist) inhibits voltage-gated calcium current and contractility in vascular smooth muscle from rats

J. Song, Paul R Standley, F. Zhang, D. Joshi, S. Gappy, J. R. Sowers, J. L. Ram

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

Tamoxifen (Tx) has been used in breast cancer treatment and prophylaxis because of its antiestrogenic activity; however, Tx may also have beneficial cardiovascular effects and other actions mediated by mechanisms other than estrogen receptors. Previous studies showing interactions of Tx with Ca++- channel blockers suggested that Tx may affect Ca++ channels, an hypothesis that was investigated using whole cell patch clamp techniques in vascular smooth muscle cells (cell line A7r5 and freshly dissociated cells) and by determining effects on contractions of isolated blood vessels. Tx reduced current through L-type Ca++ channels, with an ID50 of 2 x 10-6 M when applied by cumulative addition to A7r5 cells. With acute application, 10-6 M Tx significantly reduced L-type current in A7r5 cells within 2 min to 68% of control (vehicle, 0.1% ethanol) in A7r5 cells, 67% of control in aortic vascular smooth muscle cells, and 60% of control in tail artery vascular smooth muscle cells. Tx also decreased the rate of inactivation of L-type current. Inhibition of T-type current by Tx was less than for L-type current but was significant at 10-5 M Tx. Treatment of tail artery rings with Tx (10-5 M, 15 min; 10-6 M, 4 hr) reduced K+-elicited contractions. Since therapeutic concentrations of Tx during treatment may exceed 10-6 M, these effects of Tx on vascular smooth muscle Ca++ channels and vessel contractions may have a role in the efficacy and side-effects of Tx treatment.

Original languageEnglish (US)
Pages (from-to)1444-1453
Number of pages10
JournalJournal of Pharmacology and Experimental Therapeutics
Volume277
Issue number3
StatePublished - 1996
Externally publishedYes

Fingerprint

Estrogen Antagonists
Tamoxifen
Vascular Smooth Muscle
Calcium
Smooth Muscle Myocytes
Tail
Arteries
Patch-Clamp Techniques
Estrogen Receptors
Blood Vessels

ASJC Scopus subject areas

  • Pharmacology

Cite this

Tamoxifen (estrogen antagonist) inhibits voltage-gated calcium current and contractility in vascular smooth muscle from rats. / Song, J.; Standley, Paul R; Zhang, F.; Joshi, D.; Gappy, S.; Sowers, J. R.; Ram, J. L.

In: Journal of Pharmacology and Experimental Therapeutics, Vol. 277, No. 3, 1996, p. 1444-1453.

Research output: Contribution to journalArticle

@article{02dc72d3c8de4c018f43bdd5c1665d87,
title = "Tamoxifen (estrogen antagonist) inhibits voltage-gated calcium current and contractility in vascular smooth muscle from rats",
abstract = "Tamoxifen (Tx) has been used in breast cancer treatment and prophylaxis because of its antiestrogenic activity; however, Tx may also have beneficial cardiovascular effects and other actions mediated by mechanisms other than estrogen receptors. Previous studies showing interactions of Tx with Ca++- channel blockers suggested that Tx may affect Ca++ channels, an hypothesis that was investigated using whole cell patch clamp techniques in vascular smooth muscle cells (cell line A7r5 and freshly dissociated cells) and by determining effects on contractions of isolated blood vessels. Tx reduced current through L-type Ca++ channels, with an ID50 of 2 x 10-6 M when applied by cumulative addition to A7r5 cells. With acute application, 10-6 M Tx significantly reduced L-type current in A7r5 cells within 2 min to 68{\%} of control (vehicle, 0.1{\%} ethanol) in A7r5 cells, 67{\%} of control in aortic vascular smooth muscle cells, and 60{\%} of control in tail artery vascular smooth muscle cells. Tx also decreased the rate of inactivation of L-type current. Inhibition of T-type current by Tx was less than for L-type current but was significant at 10-5 M Tx. Treatment of tail artery rings with Tx (10-5 M, 15 min; 10-6 M, 4 hr) reduced K+-elicited contractions. Since therapeutic concentrations of Tx during treatment may exceed 10-6 M, these effects of Tx on vascular smooth muscle Ca++ channels and vessel contractions may have a role in the efficacy and side-effects of Tx treatment.",
author = "J. Song and Standley, {Paul R} and F. Zhang and D. Joshi and S. Gappy and Sowers, {J. R.} and Ram, {J. L.}",
year = "1996",
language = "English (US)",
volume = "277",
pages = "1444--1453",
journal = "Journal of Pharmacology and Experimental Therapeutics",
issn = "0022-3565",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "3",

}

TY - JOUR

T1 - Tamoxifen (estrogen antagonist) inhibits voltage-gated calcium current and contractility in vascular smooth muscle from rats

AU - Song, J.

AU - Standley, Paul R

AU - Zhang, F.

AU - Joshi, D.

AU - Gappy, S.

AU - Sowers, J. R.

AU - Ram, J. L.

PY - 1996

Y1 - 1996

N2 - Tamoxifen (Tx) has been used in breast cancer treatment and prophylaxis because of its antiestrogenic activity; however, Tx may also have beneficial cardiovascular effects and other actions mediated by mechanisms other than estrogen receptors. Previous studies showing interactions of Tx with Ca++- channel blockers suggested that Tx may affect Ca++ channels, an hypothesis that was investigated using whole cell patch clamp techniques in vascular smooth muscle cells (cell line A7r5 and freshly dissociated cells) and by determining effects on contractions of isolated blood vessels. Tx reduced current through L-type Ca++ channels, with an ID50 of 2 x 10-6 M when applied by cumulative addition to A7r5 cells. With acute application, 10-6 M Tx significantly reduced L-type current in A7r5 cells within 2 min to 68% of control (vehicle, 0.1% ethanol) in A7r5 cells, 67% of control in aortic vascular smooth muscle cells, and 60% of control in tail artery vascular smooth muscle cells. Tx also decreased the rate of inactivation of L-type current. Inhibition of T-type current by Tx was less than for L-type current but was significant at 10-5 M Tx. Treatment of tail artery rings with Tx (10-5 M, 15 min; 10-6 M, 4 hr) reduced K+-elicited contractions. Since therapeutic concentrations of Tx during treatment may exceed 10-6 M, these effects of Tx on vascular smooth muscle Ca++ channels and vessel contractions may have a role in the efficacy and side-effects of Tx treatment.

AB - Tamoxifen (Tx) has been used in breast cancer treatment and prophylaxis because of its antiestrogenic activity; however, Tx may also have beneficial cardiovascular effects and other actions mediated by mechanisms other than estrogen receptors. Previous studies showing interactions of Tx with Ca++- channel blockers suggested that Tx may affect Ca++ channels, an hypothesis that was investigated using whole cell patch clamp techniques in vascular smooth muscle cells (cell line A7r5 and freshly dissociated cells) and by determining effects on contractions of isolated blood vessels. Tx reduced current through L-type Ca++ channels, with an ID50 of 2 x 10-6 M when applied by cumulative addition to A7r5 cells. With acute application, 10-6 M Tx significantly reduced L-type current in A7r5 cells within 2 min to 68% of control (vehicle, 0.1% ethanol) in A7r5 cells, 67% of control in aortic vascular smooth muscle cells, and 60% of control in tail artery vascular smooth muscle cells. Tx also decreased the rate of inactivation of L-type current. Inhibition of T-type current by Tx was less than for L-type current but was significant at 10-5 M Tx. Treatment of tail artery rings with Tx (10-5 M, 15 min; 10-6 M, 4 hr) reduced K+-elicited contractions. Since therapeutic concentrations of Tx during treatment may exceed 10-6 M, these effects of Tx on vascular smooth muscle Ca++ channels and vessel contractions may have a role in the efficacy and side-effects of Tx treatment.

UR - http://www.scopus.com/inward/record.url?scp=0030439246&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030439246&partnerID=8YFLogxK

M3 - Article

C2 - 8667209

AN - SCOPUS:0030439246

VL - 277

SP - 1444

EP - 1453

JO - Journal of Pharmacology and Experimental Therapeutics

JF - Journal of Pharmacology and Experimental Therapeutics

SN - 0022-3565

IS - 3

ER -